Aytu Biopharma (AYTU) Raw Materials (2019 - 2026)

Aytu Biopharma (AYTU) has 8 years of Raw Materials data on file, last reported at $1.4 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $1.4 million, up 155.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 155.49% YoY), and the FY2025 annual result was $1.1 million, up 319.17% from the prior year.
• Raw Materials grew to $1.4 million in Q1 2026 per AYTU's latest filing, from $1.2 million in the prior quarter.
• Over five years, Raw Materials peaked at $2.2 million in Q1 2023 and troughed at $266000.0 in Q2 2024.
• A 5-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2024 and 2025: Raw Materials slumped 79.55% in 2024, then jumped 319.17% in 2025.
• A 5-year view of Raw Materials shows it stood at $1.8 million in 2022, then fell by 7.39% to $1.7 million in 2023, then sank by 70.13% to $494000.0 in 2024, then surged by 144.94% to $1.2 million in 2025, then grew by 13.39% to $1.4 million in 2026.
• Business Quant data shows AYTU's Raw Materials at $1.4 million in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.